Sharekhan has given Buy recommendation for Sun Pharmaceutical Industries with a target price of Rs. 810 in its research report issued on May 27, 2021
Sharekhan’s research report on Sun Pharmaceutical Industries
Q4FY21 numbers were strong with Sun Pharma reporting higher-than-expected earnings. India business growth is expected to backed by new product launches, improving the field force’s productivity and expected traction in existing business. In FY21 Sun Pharma has launched 31 products, which would gather pace going ahead. The outlook for the US business has improved, following a pick-up in the lucrative specialty business with the management eyeing market share gains. The management sees uncertainties to stay due to Covid, however it stays focused on growing the performance across segments as the long term growth levers are intact.
We retain Buy recommendation on the stock with a revised PT of Rs. 810.